Medprime Technologies, a Thane-based medical device company focused on developing cutting-edge healthcare solutions in diagnostics, has announced the launch of Micalys, first-of-its-kind innovative artificial intelligence (AI)-integrated digital microscopy platform that is set to revolutionise digital pathology in India. 

Medprime was founded by four biomedical engineering postgraduates from IIT Bombay in 2014. It is funded by the USAID-supported SAMRIDH fund, managed by IPE Global, as well as BIG and SBIRI grants from BIRAC.

Micalys, a groundbreaking device, is set to become an essential tool in diagnostic laboratories, research facilities, and educational institutions across the country, proving beneficial for pathologists as well as for patients belonging to every strata of population.

The reducing number of pathologists globally as well as in the country coupled with increasing numbers of patients and preventive testing has burdened the practising pathologists with heavy work loads. With most experts being concentrated in Tier 1 cities, the need for transportation of samples from rural areas and smaller towns to large cities has grown. With the use of Micalys in labs, the requirement for a pathologist’s physical presence in the lab for diagnosis is eliminated and a doctor sitting anywhere in the world can report on a case with full confidence.

Micalys has immense potential for malaria, filaria and TB screening in resource limited areas. ML based analysis algorithms can be used to assist in the diagnosis of these infections in the absence of trained technicians, thus addressing a critical gap in the current diagnostic landscape.